A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis

Trial Profile

A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms 16Y-LTF; 20Y-LTF; 21Y-LTF
  • Sponsors Berlex Laboratories
  • Most Recent Events

    • 30 Jun 2010 Added trial investigator, actual no. of pts and updated trial comment.
    • 08 Jun 2010 Results from the 16-year follow-up to the pivotal Betaferon trial published in Neurology, according to a Bayer HealthCare media release.
    • 29 Apr 2009 New data analyses presented at 61st Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top